Patients with asthma who completed weekly symptom questionnaires and viewed educational information saw greater QoL improvements.

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Air pollution, built environment, and ambient temperature jointly contribute to incident asthma risk, according to a recent study.